Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 9/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.60 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.60 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | CD44 | P16070 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29521679 | 1.00 | PNMT (0.60) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| Hydrochloric Acid SCHEMBL4517857 | 0.98 | PNMT (0.58) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| Hydrochloric Acid SCHEMBL3285222 | 0.98 | PNMT (0.58) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL329985 | 0.92 | ASIC3 (0.60) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL29657674 | 0.92 | ASIC3 (0.60) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| Hydrochloric Acid SCHEMBL1948668 | 0.90 | ASIC3 (0.58) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| Hydrochloric Acid SCHEMBL4514463 | 0.90 | ASIC3 (0.58) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL4718936 | 0.88 | PNMT (0.47) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL7207915 | 0.88 | PNMT (0.50) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL1947625 | 0.87 | HTR2C (0.57) | PNMTADRA2AADRA2BADRA2CDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 281 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102459264-A | Pyrimidine inhibitors of kinase activity | ABBOTT LAB | 2012-05-16 | — | — | CN | claimed |
| EP-1227803-B1 | COMPOUNDS FOR INHIBITING IAPP-ASSOCIATED AMYLOID DEPOSITS | BELLUS HEALTH INTERNATIONAL LTD (CH) | 2010-05-05 | — | — | EP | claimed |
| EP-1828185-A2 | 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2007-09-05 | — | — | EP | claimed |
| WO-2006068826-A2 | 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-06-29 | — | — | WO | claimed |
| US-6608193-B2 | Forming an intermediate by reacting the support-bound amino-substituted-tetrahydroisoquinoline compound with a reagent; and cyclizatively cleaving support-bound amino-substituted-tetrahydroisoquinoline compound | THE PROCTER & GAMBLE COMPANY | 2003-08-19 | — | — | US | claimed |
| US-6562836-B1 | Islet amyloid polypeptide (IAPP) is known to be capable of forming fibrils which are deposited in the pancreas of patients wtih type II diabetes | QUEEN'S UNIVERSITY OF KINGSTON (CA) | 2003-05-13 | — | — | US | claimed |
| US-20020077480-A1 | Methods for synthesis of amino-tetrahydroisoquinoline ring compounds | PROCTER & GAMBLE COMPANY, THE | 2002-06-20 | — | — | US | claimed |
| US-6274594-B1 | ANTICONVULSANTS, ANALGESICS; NERUOPATHIC, CANCER AND DENTAL PAIN; | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-08-14 | — | — | US | claimed |
| EP-1032570-A1 | ISOQUINOLINE DERIVATIVES AND THEIR THERAPEUTICAL USE | SMITHKLINE BEECHAM PLC (GB) | 2000-09-06 | — | — | EP | claimed |
| WO-1999025709-A1 | ISOQUINOLINE DERIVATIVES AND THEIR THERAPEUTICAL USE | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-05-27 | — | — | WO | claimed |
| US-12612424-B2 | HPK1 inhibitors and uses thereof | REGOR PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| CN-114315796-B | Compounds used as HPK1 kinase inhibitor, preparation method and application thereof | 中国药科大学 | 2024-03-26 | — | — | CN | disclosed |
| US-11918582-B2 | Pyrazole pyrimidine compounds and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20230210854-A1 | MONO- AND COMBINATION THERAPIES | RECURIUM IP HOLDINGS, LLC | 2023-07-06 | — | — | US | disclosed |
| WO-2023109909-A1 | AROMATIC HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND USES THEREOF | 上海翊石医药科技有限公司 | 2023-06-22 | — | — | WO | disclosed |
| WO-1995018619-A1 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-07-13 | — | — | WO | disclosed |
| WO-1988003137-A1 | TETRAHYDROISOQUINOLIN-2-YL DERIVATIVES OF CARBOXYLIC ACIDS AS THROMBOXANE A2 ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1988-05-05 | — | — | WO | disclosed |
| EP-0049135-B1 | ANTIALLERGIC IMIDODISULFAMIDES | SMITHKLINE BECKMAN CORPORATION (US) | 1984-04-11 | — | — | EP | disclosed |
| EP-0049135-A1 | Antiallergic imidodisulfamides | SMITHKLINE BECKMAN CORPORATION (US) | 1982-04-07 | — | — | EP | disclosed |
| US-4321254-A | Antiallergic imidodisulfamides | SMITHKLINE CORPORATION (US) | 1982-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612424-B2 | HPK1 inhibitors and uses thereof | NEK11, NEK1, CSNK1A1 | PNMT 3161/4885ADRA2A 855/4885ADRA2B 1151/4885 |
| US-11918582-B2 | Pyrazole pyrimidine compounds and uses thereof | DCK, MCL1, DTYMK | PNMT 2323/4885ADRA2A 4599/4885ADRA2B 4031/4885 |
| US-20020077480-A1 | Methods for synthesis of amino-tetrahydroisoquinoline ring compounds | ASNS, QPCT, DAO | PNMT 26/4885ADRA2A 3665/4885ADRA2B 3599/4885 |
| US-20230210854-A1 | MONO- AND COMBINATION THERAPIES | TP53, BRCA1, MCL1 | PNMT 1888/4885ADRA2A 2826/4885ADRA2B 2503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.